|Bid||16.33 x 800|
|Ask||16.45 x 1200|
|Day's range||15.53 - 16.55|
|52-week range||15.53 - 236.50|
|Beta (5Y monthly)||1.89|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.